Cgp 43182 is a potent inhibitor of group IIA secreted phospholipase A2 (group IIA sPLA2) activity in vitro. Cgp 43182 is a potent anti-inflammatory drug useful for preventing the consequences of a concerted action of cytokine-stimulated pro-inflammatory genes mediated by NFkappaB.
